Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction, leading to persistently elevated blood glucose levels. It accounts for approximately 90–95% of all diabetes cases and has reached epidemic proportions globally, with the International Diabetes Federation estimating over 460 million adults currently affected. The condition develops gradually, often over years, and many individuals remain undiagnosed until complications arise. Understanding the disease mechanism, risk factors, and treatment options is essential for effective management and prevention of serious complications.

In a healthy body, the pancreatic beta cells produce insulin, which acts as a key to allow glucose from the bloodstream into cells for energy. In type 2 diabetes, two interrelated defects occur. First, insulin resistance develops — the body's cells (particularly muscle, liver, and fat cells) become less responsive to insulin, requiring increasingly larger amounts to achieve the same glucose-lowering effect. Second, beta-cell dysfunction progresses over time — the pancreas cannot keep up with the increased insulin demand, and insulin secretion gradually declines. Additionally, other pathological processes contribute: increased hepatic glucose production, impaired incretin effect, enhanced glucagon secretion, increased renal glucose reabsorption, and central nervous system dysregulation of appetite. This complex "ominous octet" of pathophysiological mechanisms explains why multi-target therapy is often necessary.

Type 2 diabetes is diagnosed using one or more of the following criteria (confirmed on a repeat test unless unequivocal hyperglycemia is present): Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) after at least 8 hours of fasting. HbA1c ≥6.5% (48 mmol/mol) — this glycated hemoglobin test reflects average blood glucose over the preceding 2–3 months and does not require fasting. Oral glucose tolerance test (OGTT) — 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) after a 75 g glucose load. Random plasma glucose ≥200 mg/dL with classic symptoms (polyuria, polydipsia, unexplained weight loss). Prediabetes is identified when values fall between normal and diabetic thresholds: FPG 100–125 mg/dL (impaired fasting glucose), OGTT 2-hour value 140–199 mg/dL (impaired glucose tolerance), or HbA1c 5.7–6.4%. Prediabetes significantly increases the risk of progression to diabetes and cardiovascular disease.

Major risk factors for T2DM include: Overweight/obesity (especially central/visceral adiposity — waist circumference >94 cm in men, >80 cm in women in European populations). Family history — having a first-degree relative with T2DM doubles the risk. Physical inactivity — sedentary lifestyle increases risk by 20–30%. Age >45 years, though T2DM is increasingly diagnosed in younger adults and adolescents. Ethnicity — higher prevalence in South Asian, African, Caribbean, and Hispanic populations. History of gestational diabetes — women who had gestational diabetes have a 50% lifetime risk of developing T2DM. Polycystic ovary syndrome (PCOS). Metabolic risk factors include hypertension, dyslipidemia (high triglycerides, low HDL cholesterol), and previous cardiovascular events.

Lifestyle modification is the foundation of T2DM management and should continue alongside any pharmacotherapy. Dietary changes should focus on reducing overall caloric intake, emphasizing whole grains, vegetables, legumes, lean proteins, and healthy fats while limiting refined carbohydrates, sugar-sweetened beverages, and processed foods. A Mediterranean-style diet has shown particular benefits for glycemic control and cardiovascular risk reduction. Carbohydrate counting or the "plate method" (half plate non-starchy vegetables, quarter lean protein, quarter whole grains) can help structure meals. Physical activity — at least 150 minutes/week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming) plus resistance training 2–3 times weekly. Exercise improves insulin sensitivity for 24–72 hours after each session. Weight management — a weight loss of 5–7% significantly improves glycemic control; structured programs targeting 15% weight loss can achieve diabetes remission in some patients.

Metformin remains the first-line pharmacological agent for most patients with T2DM. It reduces hepatic glucose production, improves insulin sensitivity, and lowers HbA1c by approximately 1.0–1.5%. It is weight-neutral or promotes modest weight loss, has a well-established safety profile, and is inexpensive. GI side effects (nausea, diarrhea) can be minimized by slow dose titration and using the extended-release formulation. It is contraindicated in severe renal impairment (eGFR <30 mL/min). SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block glucose reabsorption in the kidneys, producing glucosuria. They reduce HbA1c by 0.5–1.0%, promote weight loss (2–3 kg), lower blood pressure, and have proven cardiovascular and renal protective benefits. Key side effects include genital mycotic infections and, rarely, diabetic ketoacidosis. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. They reduce HbA1c by 1.0–1.8%, promote significant weight loss (3–7 kg, up to 15% with higher doses), and offer cardiovascular protection. Available as weekly subcutaneous injections or oral formulation (oral semaglutide). GI side effects (nausea, vomiting) usually diminish over time.

DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin) enhance endogenous incretin levels, reducing HbA1c by 0.5–0.8%. They are weight-neutral, well-tolerated, and taken orally once daily, but have modest efficacy and no proven cardiovascular benefit. Sulfonylureas (glimepiride, gliclazide, glipizide) stimulate insulin secretion from beta cells regardless of glucose level, reducing HbA1c by 1.0–1.5%. They are effective and inexpensive but carry risk of hypoglycemia and weight gain (2–3 kg). Gliclazide has the best safety profile in this class. Thiazolidinediones (pioglitazone) improve insulin sensitivity in adipose tissue and muscle, reduce HbA1c by 1.0–1.5%, but cause weight gain, fluid retention, and increased fracture risk. Insulin therapy becomes necessary when beta-cell function declines sufficiently. Typically, basal insulin (glargine, degludec, detemir) is added to oral agents first. If postprandial control is needed, rapid-acting insulin (lispro, aspart, glulisine) is added at meals. Insulin has no maximum dose and can achieve any glycemic target but requires careful self-monitoring and carries hypoglycemia risk.

Hypoglycemia (blood glucose <70 mg/dL or <3.9 mmol/L) is the most feared acute complication of diabetes treatment, particularly with insulin and sulfonylureas. Symptoms include trembling, sweating, palpitations, hunger, confusion, and in severe cases, loss of consciousness or seizures. The Rule of 15 is the standard treatment: consume 15 g of fast-acting carbohydrate (4 glucose tablets, 150 mL fruit juice, or 3–4 sugar cubes), wait 15 minutes, recheck glucose, and repeat if still below 70 mg/dL. For severe hypoglycemia with impaired consciousness, glucagon injection (intramuscular or intranasal) should be administered by a trained caregiver. All patients on insulin or sulfonylureas should carry glucose tablets and have a glucagon kit available.

Chronic hyperglycemia damages blood vessels and nerves throughout the body. Microvascular complications include: diabetic retinopathy (leading cause of blindness in working-age adults — annual eye screening is essential), diabetic nephropathy (diabetes is the leading cause of end-stage renal disease — monitor albumin-to-creatinine ratio and eGFR annually), and diabetic neuropathy (affects up to 50% of patients — presents as peripheral numbness/tingling, pain, or autonomic dysfunction). Macrovascular complications include coronary artery disease, cerebrovascular disease, and peripheral arterial disease — patients with T2DM have a 2–4 fold increased cardiovascular risk. Comprehensive management targets multiple risk factors simultaneously: HbA1c <7% (individualized), blood pressure <130/80 mmHg, LDL cholesterol <70 mg/dL for high-risk patients (statin therapy), and antiplatelet therapy when indicated.

Self-monitoring of blood glucose (SMBG) frequency depends on treatment regimen — patients on insulin typically check 4+ times daily, while those on oral agents alone may check less frequently. Continuous glucose monitoring (CGM) systems provide real-time glucose data and are increasingly used in T2DM, particularly for patients on insulin. HbA1c should be checked every 3–6 months. Regular follow-up should include annual comprehensive metabolic panel, lipid profile, urinary albumin screening, dilated eye exam, comprehensive foot examination, and dental check-up. Diabetes self-management education and support (DSMES) programs significantly improve outcomes and should be offered to all patients.

Key medications in T2DM management include metformin, empagliflozin, dapagliflozin, semaglutide, liraglutide, sitagliptin, gliclazide, pioglitazone, insulin glargine, and insulin lispro. For more information, explore related conditions on PillsCard: hypertension, hyperlipidemia, chronic kidney disease, and obesity.